Wafik S. El-Deiry: Manuscript by Tajiknia et al on Synergistic anti-tumor activity
Wafik S. El-Deiry shared a post on X:
“Manuscript from eldeiry lab, Legorreta Cancer Center by Vida Tajiknia, Am J Cancer Res, 2024 In PubMed.
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.”
Authors: Vida Tajiknia, Maximilian Pinho-Schwermann, Praveen R Srinivasan, Liz Hernandez Borrero, Leiqing Zhang, Kelsey E Huntington and Wafik S El-Deiry
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023